```html

Kawasaki Disease with Pericarditis

Overview

Kawasaki disease (KD) is an acute vasculitis that primarily affects medium‑sized arteries, most notably the coronary arteries. When inflammation spreads to the lining of the heart (the pericardium), it is termed Kawasaki disease with pericarditis. Pericarditis can cause chest pain, fluid buildup, and may increase the risk of long‑term cardiac complications.

‑ **Typical age**: 2 – 5 years old (≈80 % of cases); however, adolescents and adults can develop KD, especially atypical forms.
‑ **Sex**: Males are about 1.5–2 times more likely to be affected.
‑ **Prevalence**: In the United States, KD is the leading cause of acquired heart disease in children, with an annual incidence of ~19–20 per 100,000 children under 5 years (CDC, 2023). Pericarditis occurs in roughly 10–20 % of KD patients who develop cardiac involvement.
‑ **Geography**: Highest rates are reported in East Asia (Japan ≈ 264/100,000; Korea ≈ 115/100,000) and among children of Asian descent worldwide.

Symptoms

Symptoms of KD with pericarditis overlap with classic KD but include additional cardiac signs.

Classic Kawasaki disease features

• Fever – ≥ 5 days of high, unremitting temperature (often > 39 °C).
• Conjunctival injection – Bilateral, non‑purulent redness of the eyes.
• Oral changes – Red, cracked lips; “strawberry” tongue; diffuse erythema of the oropharynx.
• Extremity changes – Swelling or erythema of hands/feet, followed by periungual desquamation (skin peeling) after the fever subsides.
• Rash – Polymorphous, non‑vesicular rash that can be trunk‑predominant.
• Cervical lymphadenopathy – Usually unilateral node ≥ 1.5 cm.

Pericarditis‑specific signs

• Chest pain – Sharp, pleuritic, worse when lying flat and improved by leaning forward.
• Pericardial friction rub – Scratchy sound heard on auscultation.
• Shortness of breath – May indicate pericardial effusion.
• Palpitations or irregular heart rhythm – Resulting from myocardial irritation.
• Low‑grade fever or persistent fever – Even after IVIG therapy.
• Signs of tamponade (rare) – Neck vein distention, muffled heart sounds, hypotension.

Causes and Risk Factors

The exact trigger for KD remains unknown, but research points to an abnormal immune response to an infectious agent in genetically susceptible children.

Potential causes

• Infectious hypothesis – Seasonal peaks and clustering of cases suggest viral (e.g., coronavirus, adenovirus) or bacterial (e.g., Staphylococcus aureus) involvement, though no single pathogen has been confirmed.
• Immune dysregulation – Elevated cytokines (TNF‑α, IL‑6, IL‑1β) drive widespread endothelial inflammation.
• Genetic predisposition – Polymorphisms in ITPKC, CASP3, and FCGR2A genes increase susceptibility (NIH, 2022).

Risk factors for pericarditis in KD

• Delayed diagnosis or treatment (> 10 days from fever onset).
• Male sex and age < 2 years (younger children tend to have more severe inflammation).
• High initial inflammatory markers (CRP > 13 mg/dL, ESR > 80 mm/h).
• Concurrent coronary artery aneurysms or myocarditis.

Diagnosis

Diagnosis combines clinical criteria, laboratory data, and imaging.

Clinical criteria

Full (classic) KD requires ≥ 5 days of fever plus *four* of the five principal clinical features listed above. Incomplete KD is suspected when fever lasts ≥ 5 days with fewer than four features but with supportive lab or echocardiographic findings.

Laboratory tests

• Inflammatory markers – Elevated C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR).
• Complete blood count – Neutrophilia, anemia, thrombocytosis (often after day 7).
• Liver enzymes – Mild transaminitis.
• Urine analysis – Sterile pyuria or hematuria.
• Serum albumin – Low levels (< 3.0 g/dL) correlate with higher cardiac risk.

Imaging

• Echocardiography – First‑line to assess coronary arteries, pericardial effusion, and ventricular function. Pericardial fluid > 5 mm is considered abnormal.
• Cardiac MRI – Provides detailed tissue characterization, useful when echocardiography is inconclusive.
• Chest X‑ray – May reveal an enlarged cardiac silhouette in large effusions.

Electrocardiogram (ECG)

Can show diffuse ST‑segment elevation, PR‑segment depression, or arrhythmias associated with pericardial irritation.

Treatment Options

The therapeutic goal is to halt inflammation, prevent coronary artery damage, and resolve pericardial involvement.

First‑line therapy

• Intravenous Immunoglobulin (IVIG) – 2 g/kg given as a single infusion within the first 10 days of fever. Reduces coronary aneurysm risk from ~25 % to < 5 % (Mayo Clinic, 2023).
• Aspirin – High‑dose (80–100 mg/kg/day) until the fever resolves, then low‑dose (3–5 mg/kg/day) for anti‑platelet effect for 6–8 weeks or longer if coronary abnormalities persist.

Adjunctive therapies for pericarditis

• Corticosteroids – Methylprednisolone 2 mg/kg/day (or pulse 30 mg/kg) for IVIG‑resistant cases or when pericardial effusion is large.
• Biologic agents – Infliximab (anti‑TNF) or anakinra (IL‑1 receptor antagonist) have shown benefit in refractory KD with cardiac involvement (Cleveland Clinic, 2022).
• Colchicine – 0.5 mg twice daily for children > 6 years; helps reduce pericardial inflammation and recurrent effusion.

Procedures

• Pericardiocentesis – Needle drainage of large or tamponade‑producing effusions; performed under echocardiographic guidance.
• Coronary artery surveillance – Serial echocardiograms at 2, 4, 6 weeks, then at 6 months, and annually if aneurysms persist.

Lifestyle & supportive care

• Fever control with acetaminophen.
• Hydration and nutrition; children may have decreased appetite.
• Rest and avoidance of strenuous activity for at least 4 weeks after fever resolution, longer if coronary abnormalities exist.

Living with Kawasaki disease with pericarditis

Long‑term management focuses on cardiac monitoring, medication adherence, and normal childhood development.

Daily management tips

• Medication schedule – Use a pill‑box or smartphone reminder for aspirin and any prescribed steroids/biologics.
• Watch for recurrence – Keep a fever diary; note any chest discomfort, especially after exercise.
• Physical activity – Follow cardiology recommendations; most children can resume school and light play after 2 weeks of afebrile status, but high‑intensity sports may be delayed 3–6 months.
• Vaccinations – Routine immunizations are safe; live vaccines should be deferred for 6 months after high‑dose steroids.
• Family education – Teach caregivers how to auscultate for rubs and when to call the doctor.

Follow‑up schedule

1. 2‑week post‑IVIG echocardiogram.
2. 4‑week and 6‑week visits for labs (CRP, ESR) and clinical exam.
3. 6‑month and 12‑month cardiac imaging if any coronary changes.
4. Annual cardiology review for children with persistent aneurysms or large pericardial effusions.

Prevention

Because the exact trigger is unknown, primary prevention is limited. Strategies focus on early recognition and prompt treatment.

• Public awareness – Educate parents and primary‑care providers about the classic fever + rash + red eyes triad.
• Prompt medical evaluation – Any child with fever > 5 days and two or more KD signs should be evaluated urgently.
• Infection control – General hand‑hygiene and respiratory etiquette may reduce exposure to potential viral triggers.

Complications

If untreated or inadequately treated, KD with pericarditis can lead to serious outcomes.

• Coronary artery aneurysms – Present in 15–25 % of untreated cases; risk of thrombosis, myocardial infarction, or sudden cardiac death.
• Myocarditis – Inflammation of the heart muscle causing reduced ejection fraction.
• Cardiac tamponade – Accumulation of fluid that compresses the heart, a life‑threatening emergency.
• Persistent pericardial effusion – May require repeat drainage or surgical pericardial window.
• Arrhythmias – Atrial or ventricular ectopy linked to inflammation.
• Long‑term vascular disease – Early atherosclerosis and endothelial dysfunction reported in survivors.

When to Seek Emergency Care

References

• Mayo Clinic. “Kawasaki disease.” Updated 2023. https://www.mayoclinic.org
• Centers for Disease Control and Prevention. “Kawasaki Disease (Mucocutaneous Lymph Node Syndrome).” 2023. https://www.cdc.gov/kawasaki/
• National Institutes of Health. “Kawasaki disease: clinical features and management.” 2022. https://www.nhlbi.nih.gov
• Cleveland Clinic. “Kawasaki Disease and Cardiac Complications.” 2022. https://my.clevelandclinic.org
• World Health Organization. “Guidelines for the Management of Kawasaki Disease.” 2021. https://www.who.int
• Newburger JW, et al. “Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease.” *Circulation*. 2020;141:e123‑e147.

```